Exploring Novel Treatment Targets and Emerging Therapies for Multiple Sclerosis

Intended Audience: MS specialists, neurologists and their MS clinical teams, including NPs/PAs, nurses, and pharmacists

Advances in our understanding of the pathogenesis and pathophysiology of multiple sclerosis (MS) have led to the discovery of novel treatment targets for this disease, including Bruton's tyrosine kinase (BTK).

Although current disease-modifying therapies (DMTs) for the treatment of MS have shown efficacy in preventing disease progression and mitigating relapse activity, many patients still experience disease progression independent of relapse activity. Importantly, residual disease activity in the central nervous system (CNS) has been associated with more severe clinical outcomes in MS and pose a major treatment gap. BTK inhibitors can cross the blood brain barrier and directly target adaptive and innate immune mechanisms in the periphery and central nervous system involved in MS, which may in turn help to address residual disease activity.

Join us to learn more about:

• Developments in treatment targeting and the role of BTK signaling in MS pathogenesis
• The latest mechanism of action, safety, and efficacy clinical trial data for BTK inhibitors
• Strategies to incorporate evidence into clinical practice to optimize outcomes for patients with MS

• Examine key drivers of multiple sclerosis (MS) pathogenesis and the specificity of novel therapeutic targets, particularly the role of Bruton's tyrosine kinase signaling in MS pathophysiology
• Evaluate the latest clinical trial data on the mechanism of action, efficacy, and safety of Bruton's tyrosine kinase inhibitors
• Apply the expert strategies to incorporate evolving evidence into patient-centered management planning to optimize quality of life and outcomes for individuals with MS

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0.52 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Robert Fox, MD (Speaker)
  
  Advisory Board or Panel – AB Science, Biogen, Bristol-Myers Squibb
  Consultant – AB Science, Biogen, Bristol-Myers Squibb
  Grants / Research Support – Biogen, Novartis, Sanofi
  The relationships reported above are related to the following therapeutic area: Neurology
• Tanuja Chitnis, MD, FAAN (Speaker)
  
  Advisory Board or Panel – Genentech-Roche, Novartis, Sanofi, Tiziana Life Sciences
  Consultant – Biogen, Genentech-Roche, Novartis, Siemens
  Grants / Research Support – Bristol-Myers Squibb, Genentech-Roche, Novartis, Octave Bioscience, Sanofi
  The relationships reported above are related to the following therapeutic area: Neurology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Michele B Kaufman, PharmD, BCGP (Reviewer)
• Soundarya Gowda, MD (Planner)
• Lisa Wakefield, MSN, APRN, FNP-BC (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.